Orphan Access Initiative
← Back to OAI

Rare Disease Intelligence PlatformNexus

A rare disease intelligence platform connecting education, clinical research, and orphan drug innovation.

The first AI platform built for rare disease
Scroll to explore Nexus
Patient Nexus

Educational support for patients and families navigating a rare disease diagnosis.

Enter→
Clinical Nexus

A research copilot for physicians, researchers, and students in the rare disease space.

Enter→
Nexus Diligence

Structured, investor-grade diligence on orphan drug candidates.

Enter→

What Nexus Is

Rare disease has never had a general-purpose AI platform built for it. Nexus is the first publicly available AI platform designed specifically for rare disease, not a general medical chatbot repurposed for this use.

That distinction matters because rare disease is not one problem — it’s three, held together by the same underlying science. A family needs a diagnosis explained in language they can actually use. A physician or researcher needs a fast, evidence-grounded way to move through a literature base too fragmented and too thin for any one person to track alone. An investor or drug developer needs a disciplined, structured read on whether a therapeutic candidate is worth the capital and years it will take to bring forward.

Patient Nexus, Clinical Nexus, and Nexus Diligence are built for exactly those three audiences. Each is scoped, worded, and grounded differently for the person using it — but each draws on the same underlying understanding of the disease in question, so the ecosystem moves together instead of in three disconnected directions.

7,000–10,000
Rare diseases identified to date
Estimated range, NORD / EURORDIS
~72%
Believed to have a genetic origin
EURORDIS estimate
4–7 yrs
Average wait for an accurate diagnosis
Commonly reported across patient surveys

Three Specialized AI Modules for Rare Disease

01

Patient Nexus

For patients and families who need a diagnosis explained like a person would explain it.

Who it’s for

Patients and families who need a rare disease explained in language they can actually understand — without a wall of jargon.

What it does

Rare disease information online is written for clinicians, not for the people living the diagnosis. Patient Nexus explains a condition, its genetics, and its treatment landscape in plain language, and says so clearly when something is uncertain rather than making a rare disease sound simpler than it is. It will not diagnose or tell you what to do about a specific set of symptoms — it will help you ask your own doctor a better question.

Enter Patient Nexus→
02

Clinical Nexus

For physicians, researchers, and students who need a research copilot that won't invent a citation.

Who it’s for

Physicians, researchers, and students who need a fast, evidence-grounded research copilot for rare disease literature and mechanisms.

What it does

Rare disease literature is scattered across small cohorts, case reports, and trials that rarely surface in a standard search. Clinical Nexus moves quickly through mechanism, pathway, clinical evidence, and open questions without collapsing into a generic summary. It is explicit about what is established, what is preliminary, and what is genuinely contested — and says plainly when it doesn't have a reliable source, rather than fabricate one.

Enter Clinical Nexus→
03

Nexus Diligence

For investors, biotech teams, and drug developers evaluating an orphan drug candidate.

Who it’s for

Investors, biotech teams, and drug developers who need a structured, analytical evaluation of an orphan drug candidate before committing capital or resources.

What it does

Assessing a rare disease therapeutic means reasoning across science, regulation, epidemiology, and pricing at once — and rare disease markets don't behave like the rest of pharma. Nexus Diligence takes a structured profile of a candidate and returns an analyst-grade assessment: scientific footing, clinical outlook, market and epidemiology, pricing, competitive landscape, and the investment case for and against. It flags missing or uncertain data instead of inventing numbers to fill the gap.

Enter Nexus Diligence→

Questions

Frequently Asked Questions About OAI Nexus

What is OAI Nexus?

OAI Nexus is the first AI platform built specifically for rare disease. It has three modules: Patient Nexus for patient education, Clinical Nexus for research, and Nexus Diligence for drug evaluation.

Is OAI Nexus the first rare disease AI platform?

Yes, OAI Nexus is believed to be the first publicly available AI platform purpose-built for rare disease, not a general medical AI adapted for rare disease.

Who is OAI Nexus for?

OAI Nexus serves three audiences: patients and families seeking rare disease education, physicians and researchers needing clinical evidence, and biotech investors and professionals evaluating orphan drugs.

What are the three modules of OAI Nexus?

Patient Nexus is for patient education, Clinical Nexus is for research professionals, and Nexus Diligence is for biotech and investment due diligence on orphan drugs.

Is OAI Nexus free to use?

Yes, OAI Nexus is free and accessible to patients, clinicians, researchers, students, and biotech professionals working in rare disease.

What is an orphan drug?

An orphan drug is a medication developed to treat a rare disease or condition. In the US, a disease is considered rare if it affects fewer than 200,000 people.

What is the Orphan Access Initiative?

The Orphan Access Initiative is a student-led research organization that built OAI Nexus to understand why promising treatments don't reach rare disease patients.